Lipella Pharmaceuticals Inc. (NASDAQ:LIPO – Get Free Report)’s stock price traded down 14.8% during mid-day trading on Tuesday . The stock traded as low as $0.3410 and last traded at $0.3410. 22,645 shares were traded during trading, a decline of 96% from the average session volume of 631,420 shares. The stock had previously closed at $0.40.
Lipella Pharmaceuticals Stock Up 2.6%
The company has a market cap of $1.62 million, a PE ratio of -0.09 and a beta of -0.08. The company has a 50-day moving average of $0.52 and a 200-day moving average of $1.05.
About Lipella Pharmaceuticals
Lipella Pharmaceuticals Inc, a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).
See Also
- Five stocks we like better than Lipella Pharmaceuticals
- What is MarketRank™? How to Use it
- Keysight Technologies’ Surge: The Market Wakes Up to This AI Play
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Is American Express the Credit Stock For a K-Shaped Economy?
- How to Invest in Insurance Companies: A Guide
- Powering Up: How a Credit Upgrade Fuels Vistra’s AI Ambitions
Receive News & Ratings for Lipella Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipella Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
